Depo-Provera Lawsuit: Mass Tort Case Leads & Case Acquisition Intelligence

As of March 2, 2026, there are 3,769 pending actions in MDL-3140. Additional cases are pending in state courts, including approximately 332 in Delaware, 72 in New York, and 21 in California. Case count has grown 3,873% since the MDL was created in February 2025.

Yes. The litigation is in an early, pre-bellwether stage with high filing activity. No settlement has been announced, and the first trial is not until December 2026. The discovery rule may extend statute of limitations for many potential plaintiffs who only recently learned of the Depo-Provera/meningioma connection.

No settlements have occurred yet. Attorney projections range from $75,000-$150,000 for monitored cases without surgery, $150,000-$500,000 for surgical cases, and $500,000-$1M+ for severe cases with significant complications. These are estimates based on comparable litigation, not guarantees.

Depo-Provera is one of the fastest-growing MDLs (over 4,700% growth in 14 months). It is smaller than mature MDLs like Talcum Powder (67K cases) or AFFF (15K cases) but growing faster than most. The pre-bellwether stage, recent FDA warning, and pending preemption ruling suggest continued growth potential with favorable timing for new market entrants.

The first bellwether trial is scheduled for December 7-14, 2026. Four additional pilot trials are scheduled for January 2027. The May 2026 Daubert hearings on general causation will be a critical milestone preceding the trials.

Law firms can generate Depo-Provera lawsuit leads through several channels: organic SEO targeting lawsuit-related search terms, Google Ads for high-intent queries, Local Service Ads (LSAs) for Google-screened credibility, social media advertising on Facebook/Instagram targeting the plaintiff demographic, and dedicated niche websites built specifically for the Depo-Provera litigation. Firms investing in owned media assets (SEO, niche sites) often achieve better long-term unit economics than those relying solely on third-party lead sources.

Yes. The December 2025 FDA warning created significant search demand for Depo-Provera lawsuit information. SEO is particularly effective because: (1) the litigation is still early-stage, meaning less entrenched competition, (2) search volume is growing as awareness spreads, and (3) content assets built now will compound in value over the litigation lifecycle. A content strategy targeting educational queries ("Depo-Provera brain tumor," "Depo-Provera lawsuit eligibility") can capture plaintiffs earlier in their research journey.

Dedicated niche sites for specific mass torts can outperform pages on a general law firm website. Benefits include: faster ranking for case-specific keywords, focused conversion optimization without competing firm priorities, cleaner attribution and analytics, and the ability to build topical authority quickly. The investment makes sense for firms committed to significant case volume in this litigation—particularly given Depo-Provera's growth trajectory and pre-bellwether timing.

Google Ads captures high-intent searches from women actively researching the lawsuit. Local Service Ads (LSAs) provide Google-verified credibility and pay-per-lead pricing. Facebook/Instagram ads enable demographic targeting aligned with Depo-Provera users (women 25-55) and support video creative explaining the meningioma connection. Most successful firms use a multi-channel approach with proper attribution tracking to optimize spend allocation across channels.

No—the litigation is still early-stage. With no bellwether trials until December 2026 and no settlement announced, firms have runway to build case inventory before resolution. The December 2025 FDA warning is driving increased awareness, and the discovery rule extends statute of limitations for many plaintiffs just learning of the connection. Firms investing in marketing infrastructure now (SEO, niche sites, paid campaigns) will be positioned to capture cases through the settlement phase. Mass torts typically see peak filing activity in the 12-24 months before settlement, suggesting 2026-2027 remains an opportune window.

Yes. Smaller firms can sign cases and refer to or co-counsel with established mass tort firms handling the litigation. This allows participation without the overhead of MDL leadership or bellwether preparation. Referral fees typically range from 25-40% of the originating firm's fee. Alternatively, firms can build their own inventory and join the MDL directly—the barrier to entry is case acquisition capability, not firm size. Digital marketing (SEO, targeted ads) has leveled the playing field, allowing nimble firms to compete effectively against larger competitors.